Valuation: Everest Organics Limited

Market Cap 197.56Cr 2.06Cr 1.77Cr 1.65Cr 1.51Cr 2.84Cr 2.88Cr 20Cr 7.62Cr 99Cr 7.75Cr 7.58Cr 328.26Cr P/E 2024
675x
P/E 2025 -190x
Enterprise Value 238.8Cr 2.5Cr 2.14Cr 2Cr 1.83Cr 3.44Cr 3.48Cr 24Cr 9.22Cr 119.96Cr 9.37Cr 9.17Cr 396.77Cr EV / Sales 2024
0.75x
EV / Sales 2025 1.79x
Free-Float
23.1%
Yield 2024 *
-
Yield 2025 -
1 day-3.62%
1 week+3.04%
Current month-0.77%
1 month-3.33%
3 months+14.54%
6 months-19.32%
Current year-41.12%
1 week 250
Extreme 250
333
1 month 250
Extreme 250
339
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 106.2
Extreme 106.2
536.4
5 years 95
Extreme 95
536.4
10 years 44.45
Extreme 44.45
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 28/09/2015
Director TitleAgeSince
Director/Board Member 47 29/09/2007
Director/Board Member 48 30/07/2014
Director/Board Member 71 13/11/2024
Change 5-day change 1-year change 3-year change Capi.($)
-3.62%+3.04%-27.70%+151.10% 3.02Cr
-0.08%-1.43%+15.99%+67.26% 4.77TCr
-3.21%+1.37%+52.36%+125.75% 4.03TCr
-0.40%-1.23%-10.08%+16.08% 1.21TCr
+1.11%-1.34%+13.61%+71.49% 1.17TCr
0.00%+0.58%+30.65%+148.80% 918.98Cr
-0.39%-0.92%+19.81%+39.54% 757.14Cr
-1.35%+0.74%+47.03%-11.93% 723.59Cr
-0.64%-0.02%+19.42%+199.06% 683.65Cr
-5.36%-6.36%-36.28%+18.28% 541.95Cr
Average -1.39%-0.70%+12.48%+82.54% 1.48TCr
Weighted average by Cap. -1.16%-0.57%+24.43%+83.42%

Financials

2024 2025
Net sales 198.02Cr 2.07Cr 1.77Cr 1.66Cr 1.52Cr 2.85Cr 2.89Cr 20Cr 7.64Cr 99Cr 7.77Cr 7.6Cr 329.03Cr 159.95Cr 1.67Cr 1.43Cr 1.34Cr 1.23Cr 2.3Cr 2.33Cr 16Cr 6.17Cr 80Cr 6.28Cr 6.14Cr 265.77Cr
Net income 13.92L 14.55T 12.46T 11.66T 10.67T 20.03T 20.3T 1L 53.73T 7L 54.63T 53.44T 23.13L -1.29Cr -1L -1L -1L -98.94T -2L -2L -12.77L -5L -64.82L -5L -5L -2.14Cr
Net Debt 57Cr 59.53L 51L 47.72L 43.68L 81.97L 83.06L 5.64Cr 2.2Cr 29Cr 2.24Cr 2.19Cr 95Cr 41Cr 43.1L 36.92L 34.54L 31.62L 59.34L 60.13L 4.08Cr 1.59Cr 21Cr 1.62Cr 1.58Cr 69Cr
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
355
Date Price Change Volume
21/26/21 ₹297.80 -3.62% 568
20/26/20 ₹309.00 +4.22% 37
19/26/19 ₹296.50 -6.58% 3,439
18/26/18 ₹317.40 +10.61% 12,002
17/26/17 ₹286.95 -0.71% 1,014
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock